In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Featured article: Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
Protein measurements, alongside genetic mutations and gene expression assays, have long been used to study the heterogeneity of cancer data, specifically in Acute Myeloid Leukemia, which is not just one disease but a collection of molecularly distinct diseases. In this work we find that global proteomics can be even more useful that subtyping and can accurately predict drug response using our ex vivo drug assay across a small cohort of AML patients. We believe this type of analysis will help bring proteomics more closely aligned with the clinic as we can identify proteins that predict drug response in patient samples.
Articles
-
-
Quantitative proteomics identified circulating biomarkers in lung adenocarcinoma diagnosis
-
Glycoproteomics revealed novel N-glycosylation biomarkers for early diagnosis of lung adenocarcinoma cancers
-
Comparison of intact protein and digested peptide techniques for high throughput proteotyping of ApoE
-
Functional and quantitative evaluation of the 20S proteasome in serum and intracellular in145 moroccan patients with hematologic malignancies
-
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
-
Nanotechnologies in Glycoproteomics
-
Basics and recent advances of two dimensional- polyacrylamide gel electrophoresis
-
Recent advances in mass spectrometry based clinical proteomics: applications to cancer research
-
Aberrant glycosylation associated with enzymes as cancer biomarkers
Archival content
Trezvuy - Fotolia
Have an idea for a new thematic series?
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Editor's profile
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Featured collections
PediOme
Guest edited by Vera Ignjavtovic, Allen Everett and Hanno Steen
The Paediatric Proteomics (PediOme) is an initiative of HUPO that aims to advance the use of proteomic techniques to solve major issues in Paediatric medicine.
Proteomics in India
Guest edited by Harsha Gowda and Akhilesh Pandey
This collections features the latest advances in Proteomics research from India.
Glycoproteomics and glycomics
Guest edited by Punit Shah and Hui Zhang
This thematic series publishes both solicited and unsolicited content on the topic of protein glycosylation; one of the most common protein modifications in both normal biological processes and diseases. This series focuses on glycoproteomic or glycomic methods and their clinical applications.
-
Affiliated with
-
Clinical Proteomics is affiliated with the Human Proteome Organization (HUPO). HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
Citation Impact
5.000 - 2-year Impact Factor (2021)
4.323 - 5-year Impact Factor (2021)
0.932 - Source Normalized Impact per Paper (SNIP)
1.089 - SCImago Journal Rank (SJR)Speed
38 days to first decision for all manuscripts (Median)
50 days to first decision for reviewed manuscripts only (Median)Usage
258,084 Downloads (2021)
133 Altmetric mentions (2021)